| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
| Company Name: |
Lynnchem |
| Tel: |
86-(0)29-85992781 17792393971 |
| Email: |
info@lynnchem.com |
| Company Name: |
Novachemistry |
| Tel: |
44-20819178-90 02081917890 |
| Email: |
info@novachemistry.com |
- Reveromycin A
-
- $1760.00
-
2026-05-11
- CAS:134615-37-5
- Purity:
- Supply Ability: 10g
|
| | REVEROMYCIN A Basic information |
| Product Name: | REVEROMYCIN A | | Synonyms: | REVEROMYCIN A;ZESGNAJSBDILTB-OXVOKJAASA-N;Butanedioic acid, 1-[(2S,3R,6S,8R,9S)-3-butyl-8-[(2E,4E,6S,7S,8E)-9-carboxy-6-hydroxy-3,7-dimethyl-2,4,8-nonatrien-1-yl]-2-[(1E,3E)-4-carboxy-3-methyl-1,3-butadien-1-yl]-9-methyl-1,7-dioxaspiro[5.5]undec-3-yl] ester | | CAS: | 134615-37-5 | | MF: | C36H52O11 | | MW: | 660.79 | | EINECS: | | | Product Categories: | Epidermal Growth Factor Receptor (EGFR)Antibiotics;Interferes with Protein Synthesis;Antibiotics;Antibiotics A to;Antibiotics by Application;Antibiotics N-SAntibiotics;AntifungalAntibiotics;Mechanism of Action;Receptor Tyrosine Kinase Inhibitors;Spectrum of Activity;Antineoplastic and Immunosuppressive AntibioticsReceptor Tyrosine Kinase Biology | | Mol File: | 134615-37-5.mol |  |
| | REVEROMYCIN A Chemical Properties |
| Boiling point | 849.0±65.0 °C(Predicted) | | density | 1.21±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMF: soluble | | form | solid | | pka | 4.36±0.17(Predicted) | | color | tan |
| | REVEROMYCIN A Usage And Synthesis |
| Uses | Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF. Reveromycin A is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption. | | Uses | Reveromycin A is a spiroketal antibiotic inhibitor of EGF mitogenic activity. Inhibits the signal transduction of the epidermal growth factor. May be used | | in vivo | Reveromycin A (20 mg/kg; twice daily; i.v.; for 3 days) significantly decreases numbers of OCs without affecting numbers of osteoblasts in normal 4-week-old male Sprague-Dawley rats[2].
|
| | REVEROMYCIN A Preparation Products And Raw materials |
|